The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
George W. Sledge(Caris Life Sciences (United States)), Antonio Llombart‐Cussac(MedSIR (Spain)), Peter A. Kaufman(University of Vermont), Susana Barriga(Universitair Ziekenhuis Leuven), Olga Burdaeva(Universitair Ziekenhuis Leuven), Joohyuk Sohn(Yonsei University), Stephen Johnston(Royal Marsden NHS Foundation Trust), PierFranco Conte(University of Padua), Martin Frenzel(Universitair Ziekenhuis Leuven), Xavier Pivot(Levi Strauss (United States)), Norikazu Masuda(Kyoto University), Meena Okera(Universitair Ziekenhuis Leuven), Karla Hurt(Eli Lilly (United States)), Masakazu Toi(Mukogawa Women's University), Kenichi Inoue(Universitair Ziekenhuis Leuven), Yi Lu(Shandong Provincial Hospital), Patrick Neven(KU Leuven), Han Koh(Universitair Ziekenhuis Leuven), Eva‐Maria Grischke(Universitair Ziekenhuis Leuven)
Cited by 983
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k